P/B
34,6
Insmed
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
$25.1B
Market Cap • 11/6/2026
1999
(27 years)
Founded
2000
(26 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
16,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,3
EPS
—
Market Cap
Market Cap
25,1B
EV
24,7B
EV/Revenue
16,2
EV/EBITDA
-46
EV/EBIT
-43,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,5%
Total Yield
-0,5%
Payout
0%
Retained Earnings
-5,9B
Profitability
Gross Margin
84,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
62,1%
Capex/Revenue
2,1%
Capex/D&A
118,6%
Capex/OCF
-5,4%
SBC/OCF
—
% PPE
6,3%
% Goodwill
6,1%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
54,3%
CAGR Op. Income 5Y
8,8%
CAGR Net Income 5Y
7,4%
CAGR EPS 5Y
-6,4%
CAGR OCF 5Y
11,5%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
2,9
Quick Ratio
2,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!